Results 1 to 10 of about 1,991 (194)

Mavacamten

JACC: Advances
Matthew W. Martinez, MD, Dewey Seto, BSBA, Michael Cheung, DHSc, Michele Coiro, MBA, Niki Patel, PharmD, Arnaud Bastien, MD, Jeffrey Lockman, PhD, Sonia Afsari, MD, Milind Y. Desai, MD, MBA   +8 more
doaj   +11 more sources

Case Report: Mavacamten in mid-ventricular and apical hypertrophic cardiomyopathy—a case of targeted therapy beyond left ventricular outflow tract obstruction [PDF]

Frontiers in Medicine
BackgroundMavacamten targets cardiac myosin ATPase, reducing the formation of actin-myosin cross-bridges, which alleviates excessive myocardial contraction and improves diastolic function.
Lijia Yang, Hongyan Dai, Yuanyuan Rong
doaj   +2 more sources

Comparison of Diastolic Function Parameters After Alcohol Septal Ablation and Mavacamten Therapy in Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of Cardiovascular Development and Disease
Cardiac myosin inhibitors have been shown to improve diastolic function in patients with obstructive hypertrophic cardiomyopathy (HCM). Comparative studies to evaluate the diastolic effects of mavacamten versus alcohol septal ablation (ASA) have yet to ...
Danish Saleh, Ellis Y. Kim, Kifah Hussain, Ashraf Samhan, Meilynn Shi, Zhiying Meng, Elizabeth Schormann, Parmeen Bindra, Baljash Cheema, Dominic E. Fullenkamp, Abigail S. Baldridge, Jyothy J. Puthumana, Vera H. Rigolin, Paul C. Cremer, James D. Flaherty, Lubna Choudhury   +15 more
doaj   +2 more sources

Characteristics and Outcomes of Mavacamten Use in 2440 Patients With Obstructive Hypertrophic Cardiomyopathy [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Our objective was to assess real‐world outcomes and health care use associated with commercial mavacamten use in patients with obstructive hypertrophic cardiomyopathy.
Ingy Mahana, Angelica T. Mejia, Miriam R. Elman, Daniel Kamna, Olives Nguyen, Hailey Volk, Hongya Chen, Ahmad Masri   +7 more
doaj   +2 more sources

Cost-effectiveness analysis of mavacamten for obstructive hypertrophic cardiomyopathy: a perspective from the Chinese healthcare system [PDF]

Open Heart
Introduction The clinical management of Obstructive Hypertrophic Cardiomyopathy remains challenging, and the phase III EXPLORER-HCM trial has demonstrated that the novel cardiac myosin inhibitor Mavacamten can significantly improve patients’ symptomatic ...
Tingting Wu, Jiahao Zhang, Jialing Qian, Qingqing Jiang   +3 more
doaj   +2 more sources

Mavacamten facilitates myosin head ON‐to‐OFF transitions and shortens thin filament length in relaxed mouse skeletal muscle [PDF]

Physiological Reports
The first‐in‐its‐class cardiac drug mavacamten shifts myosin heads towards a structurally inactive position where they lay along the helical tracks of the thick filament.
Michel N. Kuehn, Nichlas M. Engels, Devin L. Nissen, Johanna K. Freundt, Weikang Ma, Samantha P. Harris, Thomas C. Irving, Wolfgang A. Linke, Anthony L. Hessel   +8 more
doaj   +2 more sources

Predictors of Higher Mavacamten Maintenance Dose in Obstructive Hypertrophic Cardiomyopathy [PDF]

Mayo Clinic Proceedings: Innovations, Quality & Outcomes
Mavacamten has emerged as an effective therapy for obstructive hypertrophic cardiomyopathy (oHCM); however, interindividual variability in maintenance dosing remains a practical challenge in clinical practice.
Mustafa Suppah, MD, Humam Abo Abdullah, MD, Amro Badr, MD, Ramzi Ibrahim, MD, Juan Farina, MD, Chadi Ayoub, MBBS, PhD, Reza Arsanjani, MD, Jeffrey Geske, MD, Said Alsidawi, MD   +8 more
doaj   +2 more sources

Mavacamten for hypertrophic obstructive cardiomyopathy [PDF]

Lancet, The, 2021
Eduard Quintana,, Fects
exaly   +3 more sources

Eighteen‐Month Real‐World Experience Using Mavacamten for Treatment of Obstructive Hypertrophic Cardiomyopathy in a Racially Diverse Population

Journal of the American Heart Association
Background Patients with obstructive hypertrophic cardiomyopathy have increased symptomatic burden. Mavacamten was recently approved for treatment of obstructive hypertrophic cardiomyopathy based on 2 randomized controlled trials.
Jose Madrazo, Lili A Barouch, Victoria Blake   +2 more
exaly   +3 more sources

Real‐World Observations in Patients With Obstructive Hypertrophic Cardiomyopathy Treated With Mavacamten: Evidence of Favorable Disease Modification [PDF]

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Mavacamten is commercially approved for use in symptomatic patients with obstructive hypertrophic cardiomyopathy. This study evaluated its real‐world impact on symptoms, echocardiographic changes, and the need for septal reduction therapy in ...
Milind Y. Desai, Andrew Gaballa, Yuichiro Okushi, Mohammed Abusafia, Shada Jadam, Katy Rutkowski, Susan Ospina, Sanaa Sultana, Maran Thamilarasan, Craig Asher, Zoran B. Popovic, Bo Xu   +11 more
doaj   +2 more sources